PR Newswire (Thu, 6:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
345 people get PRXL articles and Market Currents by email alert.
Get email alerts on PRXL »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (Apr 30, 2013)
-
PR Newswire (Apr 30, 2013)
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 2, 2013)
-
PR Newswire (Feb 20, 2013)
-
PR Newswire (Jan 29, 2013)
-
PR Newswire (Jan 22, 2013)
-
PR Newswire (Jan 10, 2013)
-
PR Newswire (Jan 4, 2013)
-
-
PR Newswire (Jan 3, 2013)
-
Strengthening Moats Mean Improving Returns For CRO InvestorsMorningstar • Mon, Dec 31, 2012
To learn more about Seeking Alpha Pro, click here.
-
Keeping an Eye on Parexel InternationalTraderMark • Tue, Apr 15, 2008 -
Parexel: Put on the RadarTate Dwinnell • Thu, Jan 10, 2008 -
-
-
Strengthening Moats Mean Improving Returns For CRO InvestorsMorningstar • Mon, Dec 31, 2012
-
-
-
Update: 8 High-Growth Healthcare Stocks With Strong Sources Of ProfitabilityKapitall • Tue, Jul 17, 2012 -
8 Undervalued Healthcare Stocks With Strong Receivable TrendsKapitall • Thu, Jun 21, 2012
-
8 High-Growth Healthcare Stocks With Strong Sources Of ProfitabilityKapitall • Tue, Jun 12, 2012
-
Sector Detector: Strong Earnings Balance Global WorriesScott Martindale • Thu, May 3, 2012 -
-
16 Rallying Healthcare Stocks Being Sold By Hedge FundsKapitall • Tue, Feb 21, 2012
-
Contract Research Organizations Still On Sale As Industry ReboundsMorningstar • Thu, Jan 12, 2012
-
Leading CROs Will Gain From Drug Research ReboundMorningstar • Mon, Oct 3, 2011
-
-
-
-
-
-
-
-
CRO Investment Opportunities Remain CompellingMorningstar • Thu, Nov 11, 2010
-
PR Newswire (Thu, 6:00AM)
-
at CNBC.com (May 13, 2013)
-
PR Newswire (Apr 30, 2013)
-
PR Newswire (Apr 30, 2013)
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 2, 2013)
-
PR Newswire (Feb 20, 2013)
-
PR Newswire (Jan 29, 2013)
-
PR Newswire (Jan 22, 2013)
-
PR Newswire (Jan 10, 2013)
-
PR Newswire (Jan 4, 2013)
-
PR Newswire (Jan 3, 2013)
-
PR Newswire (Dec 27, 2012)
-
PR Newswire (Dec 10, 2012)
-
PR Newswire (Dec 5, 2012)
-
PR Newswire (Nov 27, 2012)
PRXL vs. ETF Alternatives
Company Description
Currently, there's no company description for PRXL.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, December 27, 2012, 2:09 PM Synergy Pharmaceuticals (SGYP +5.3%) moves up after saying its commenced Phase IIb clinical trials of plecanatide, a treatment for patients with constipation-predominant irritable bowel syndrome. The trial is being conducted at 70 sites in the U.S. and includes 350 patients. Parexel International (PRXL -2%) is the contract research organization for the trial. Comment! [Healthcare, On the Move]
- Thursday, December 27, 2012, 9:17 AM Parexel (PRXL +2.1%) acquires Liquent for $72M. The shares rose after the firm raised 2Q13 revenue guidance to $415M-$420M, GAAP EPS to be in range of $0.31-$0.34 and FY13 revenue of $1.67B-$1.69B and adj. EPS to be in range of $1.36-$1.43. The acquisition is expected to have dilutive impact of $0.02-$0.04 for FY13. (PR) Comment! [On the Move, Healthcare]
- Monday, April 30, 2012, 5:20 PM PAREXEL International (PRXL): FQ3 EPS of $0.33 beats by $0.02. Revenue of $356M (+18.1% Y/Y) beats by $6M. Shares -7% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Monday, January 30, 2012, 5:45 PM More on Parexel's FQ2: Though results were only in-line, the company is guiding for FQ3 revenue of $350M-$358M ($334.2M consensus) and EPS of $0.30-$0.32 ($0.23 consensus). In addition, it's guiding for FY12 (ends in June) revenue of $1.36B-$1.375B ($1.36B consensus) and EPS of $1.09-$1.17 ($1.11 consensus). PRXL now +10% AH. (PR) Comment! [Healthcare, Earnings, On the Move]
- Wednesday, August 10, 2011, 3:56 PM Shares of Parexel (PRXL +9.3%) jump after the firm raised its FY12 outlook on revenue to $1.36B-$1.4B, from $1.34-$1.38B, and received an upgrade from Jefferies to Hold. Revenue only jumped 5% Y/Y for the firm, but backlogs increased 29% on new business wins. Comment! [On the Move, Tech]
- Monday, May 23, 2011, 12:49 PM Parexel (PRXL) has been hard hit today, -5.7% after Goldman Sachs downgrades the stock to Sell from Neutral, citing a lack of visibility, margin pressures, and overly aggressive second-half earnings growth projections. Comment! [Healthcare, On the Move, Quick Ideas]
-
Tuesday, May 3, 2011, 9:00 AM
Premarket gainers: KLIC +15%. BPI +10%. PCS +6%. FE +5%. AVP +5%. REE +4%. AVL +4%. LVLT +3%. FCEL +3%. VVUS +3%. CTIC +3%.
Losers: PRXL -18%. ANAD -15%. COOL -10%. LPSN -5%. TAP -5%. CTSH -4%. PRGO -4%. KEG -3%. CHK -3%. TTM -3%. AG -3%. OC -3%. 1 Comment [On the Move]
-
- View all 2 replies
-
-
-
Jim Van Meerten
$PRXL - 100% Barchart technical buy signals - 5 new highs and up 8.71% in hte last month - Relative strength Index 68.34% - View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
Dividend Sheet
Biggest Players Within Medical Laboratories And Research Industry ++ http://t.co/qNeUzk4 ++ $LH $DGX $CVD $ALR $PPDI $ICLR $IRWD $PRXL - View all 0 replies
-
Justin M. Hall
ZIOP, NBY, EBS, ABT, PRXL, CERN, ACT, CBRX => Notable Developments and Results 12/6/10 => Rx Investors.com => http://bit.ly/c9Kc5C - View all 0 replies
-
Alex B. Gray
Parexel $PRXL reported FY2011 Q1 revenue increased 13.9% to $295.8M and diluted earnings per share increased 42.9% to $0.30. - View all 0 replies
LATEST REPLIES
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 1 replies
-